BeiGene’s Brukinsa (zanubrutinib) Receives EC’s Approval for the Treatment of Adults with Marginal Zone Lymphoma
Shots:
- The EC has granted marketing authorization of Brukinsa for r/r MZL who have received one prior anti-CD20-based therapy
- The approval was based on results from the P-II (AGNOLIA) trial which showed a high ORR of 68% with 26% of patients achieving CR as assessed by IRC, responses were observed in all patients regardless of MZL subtypes along with a rapid and durable disease control with a median time to response of 2.8mos., was well-tolerated and safety was consistent with its established profile, low rates of discontinuation due to AEs (3.5%)
- The EC’s approval will apply to all 27 member states of the EU, Iceland, and Norway. Brukinsa has been approved in the EU for adult patients with WM
Ref: Businesswire | Image: BeiGene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
